Congratulations to the Fluid Biomed Inc. team on securing one of the largest Series A funding rounds for a MedTech company in Canada! It's been a pleasure to be early investors in this innovative #UCalgary company and to witness the tremendous progress they've made. We're thrilled to have participated in this round through the UCeed Neuro Fund. Excited to see the amazing things the future holds for Fluid Biomed!
Fluid Biomed Inc. Raises $27 Million USD in Oversubscribed Series A Financing to Advance World’s First Bioabsorbable Polymer-Based Stent To Treat Brain Aneurysms The company is thrilled to announce the successful close of an oversubscribed $27M USD Series A financing, co-led by Amplitude Ventures and an undisclosed major strategic investor. Funding will be used to advance our ReSolv™ stent, the world’s first bioabsorbable polymer-based stent to treat brain aneurysms, into additional human clinical trials. Fluid Biomed also thanks the many institutional and private investors who helped us reach this milestone, including IAG Capital Partners, LifeArc Ventures, ShangBay Capital, METIS Innovative, Accelerate Fund III managed by Yaletown Partners, Wharton Alumni Angels, Threshold Impact, Thin Air Labs, One Six 8 Ventures, HaloHealth, Bluesky Equities, UCeed Neuro Fund from the University of Calgary UCeed Investment Funds, and Adara Venture Capital. Please read the full press release here: https://bwnews.pr/4fjnycS Note that the ReSolv™ stent is an investigational medical device and not available for routine clinical use or sale.